Centerview’s Tokat Sees Potential for Mega Pharma Deals in 2026
Conditions could be ripe for the first $20 billion-plus biopharma deal in more than three years, according to Centerview Partners Co-President Eric Tokat. Tokat and Paul Weiss's Krishna Veeraraghavan joined...
By Bloomberg Markets · Bloomberg Markets
Conditions could be ripe for the first $20 billion-plus biopharma deal in more than three years, according to Centerview Partners Co-President Eric Tokat. Tokat and Paul Weiss's Krishna Veeraraghavan joined Dani Burger and Michelle F. Davis on “Bloomberg Deals” for a roundtable to discuss their outlooks for biopharma M&A. Original filename: 20260311_194745_Healthcare_M_A_Surges_Amid_Patent_Expirations_Experts_Discu.mp4 (Source: Bloomberg)